主页 > 医药科学 >
【drug-news】弗隆阻止了乳腺癌的复发
Reuters Health
Monday, October 2, 2006
LONDON (Reuters) - New 4-year clinical trial results confirm the effectiveness of Novartis's drug Femara (letrozole) in cutting the risk of breast cancer returning, researchers said on Monday.
The latest 4-year figures from a study involving nearly 5,000 patients are consistent with a previous 2-year analysis, and doctors reported no increase in adverse events with long-term treatment.
Femara belongs to a relatively new class of drugs known as aromatase inhibitors, which are prescribed for postmenopausal women with hormone-sensitive tumours.
The drugs, which cut the risk of cancer recurrence by blocking the enzyme aromatase, are given following breast cancer surgery and are usually taken for 5 years.
Data presented at the European Society of Medical Oncology Congress in Istanbul showed that women on Femara had an 18-percent reduction in their overall risk of breast cancer recurrence after an average 51 months, compared with those taking the older hormonal therapy tamoxifen.
The use of Femara also resulted in greater disease-free survival in two groups of women particularly at risk of recurrence -- those whose cancer had already spread to the lymph nodes at the time of diagnosis and those who had received chemotherapy.
In these groups, the risk of recurrence was reduced in the study by 23 percent and 26 percent, respectively. 认领了。。。
弗隆阻止了乳腺癌的复发
路透社健康消息
2006年10月2日
伦敦（路透社）：本周一，研究人员声称，一项新的为期4年的临床试验结果表明，诺华公司生产的药品弗隆（来曲唑）对于减少乳腺癌复发的危险有着肯定的疗效。
在这项近5000名患者参与的研究中，其近4年的研究数字与另一项近2年的分析结果是一致的。并且医生们发现长期治疗中不良反应事件并没有增加。
弗隆属于一类较新的药品，为芳香酶抑制剂，通常用来治疗绝经妇女的激素敏感型肿瘤。
这类药物通过阻断芳香酶达到降低肿瘤复发的作用。在乳腺癌术后给药，通常要使用5年。
伊斯坦堡的欧洲肿瘤医学协会会议上的数据显示，与服用旧有的激素治疗药物他莫西芬相比，服用弗隆的妇女在平均51个月之后，乳腺癌复发危险总体降低了18%。
弗隆的使用还使得两类特别容易肿瘤复发的妇女无瘤生存率大为增高，即诊断时已有淋巴结转移者和那些接受化疗的患者。
在这些人群中，肿瘤再发的危险在研究中分别下降了23%和26%。 [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-04 05:12
医学,生命科学网